Transgene and Nec report 100% three-year disease-free survival with TG4050
Transgene and Nec say TG4050 showed 100% three-year disease-free survival, with a Nature Communications peer-reviewed publication highlighting Phase 1 clinical and translational findings and durable neoantigen-specific T cell responses.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.